Last Updated: April 14, 2026
KPV (Lysine-Proline-Valine) is a tripeptide corresponding to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH), one of the most extensively characterized anti-inflammatory signaling molecules in vertebrate physiology. As a three-residue sequence derived from positions 11-13 of the parent α-MSH peptide, KPV retains a significant portion of the anti-inflammatory activity of the full-length hormone while completely lacking the melanotropic (pigment-stimulating) activity that characterizes the N-terminal region. This selectivity has made KPV a compelling subject for KPV peptide research across multiple domains of inflammation biology, including epithelial barrier function, innate immunity, and mucosal homeostasis. Published preclinical studies suggest that KPV interacts with melanocortin receptor signaling and intracellular transcription factor pathways, particularly nuclear factor kappa B (NF-κB), to attenuate pro-inflammatory cytokine release in a range of cellular and rodent model systems.
Quick Facts
- Sequence: Lys-Pro-Val (KPV)
- Parent molecule: α-MSH (residues 11-13, C-terminal tripeptide)
- Molecular weight: ~342.4 Da
- Classification: Anti-inflammatory tripeptide fragment
- Primary research targets: NF-κB signaling, pro-inflammatory cytokine pathways, epithelial barrier models
- Pigmentation activity: None (lacks N-terminal α-MSH residues required for MC1R pigmentation signaling)
- Storage: Lyophilized powder at -20°C; reconstituted at 2-8°C
- Regulatory status: Research chemical; not for human or animal consumption
What is KPV and where does it come from in the α-MSH molecule?
KPV is a linear tripeptide composed of L-lysine, L-proline, and L-valine connected by peptide bonds. Its sequence corresponds exactly to the final three amino acids of α-MSH, a 13-residue peptide hormone derived from proteolytic processing of proopiomelanocortin (POMC) in the pituitary and peripheral tissues. α-MSH is recognized as a pleiotropic regulator of pigmentation, energy balance, and inflammation, and published studies have shown that these functions can be partially dissected by examining sub-fragments. The N-terminal sequence of α-MSH contains the “HFRW” motif required for classical melanocortin receptor agonism at MC1R, while the C-terminal KPV sequence retains robust anti-inflammatory activity in laboratory models. Research literature frequently references the work of Catania and Lipton in the 1990s-2000s, which laid much of the groundwork for understanding how this tripeptide modulates inflammatory cascades independent of pigmentation pathways. This makes KPV a useful tool compound for dissecting inflammatory signaling in vitro and in rodent research models.
How does KPV modulate the NF-κB inflammatory pathway?
Preclinical research indicates that KPV’s anti-inflammatory activity converges substantially on the NF-κB signaling axis, a master transcriptional regulator of innate immune gene expression. Published in vitro studies using cultured macrophages, keratinocytes, and intestinal epithelial cell lines suggest that KPV attenuates NF-κB nuclear translocation following stimulation with pro-inflammatory triggers such as lipopolysaccharide (LPS), tumor necrosis factor alpha (TNF-α), or interleukin-1 beta (IL-1β). The proposed mechanism involves stabilization of the IκBα inhibitor protein and reduced phosphorylation of the p65/RelA subunit, which together limit transcription of downstream inflammatory genes including IL-6, IL-8, and cyclooxygenase-2. Importantly, Kannengiesser et al. (PMID: 15649510) demonstrated that KPV exerts anti-inflammatory effects on colonic epithelial cells through mechanisms that appear largely NF-κB dependent, providing an early reference point for subsequent gut inflammation research protocols. These findings make KPV a useful probe compound for dissecting epithelial NF-κB biology.
Why does KPV lack pigmentation activity despite being an α-MSH fragment?
The pigmentation activity of α-MSH at MC1R requires the central “core” sequence His-Phe-Arg-Trp (HFRW), which occupies positions 6-9 of the parent peptide. This tetrapeptide is the minimum pharmacophore for high-affinity melanocortin receptor binding and downstream cAMP signaling that drives eumelanin synthesis in melanocytes. KPV, representing only the C-terminal three residues, entirely lacks this HFRW motif and therefore does not engage MC1R in a manner sufficient to trigger the pigmentation cascade. Published studies suggest that the anti-inflammatory effects of KPV may instead depend on a combination of low-affinity melanocortin receptor interactions, direct intracellular effects following cellular uptake, and possibly binding to non-classical anti-inflammatory targets. This dissociation between pigmentation and immunomodulatory activity is a central reason research interest has focused on KPV as a selective anti-inflammatory probe: investigators can examine inflammation biology in rodent and cell-culture protocols without confounding pigmentation effects that would arise with full-length α-MSH or cyclic melanocortin analogs.
What antimicrobial and candidacidal activity has been reported for KPV?
Beyond its anti-inflammatory profile, published studies suggest KPV and related α-MSH fragments display direct antimicrobial activity against a range of microorganisms in laboratory assays. Research has documented candidacidal effects against Candida albicans, reductions in Staphylococcus aureus viability, and modulation of microbial biofilm formation in culture systems. The proposed mechanism involves membrane destabilization combined with interference with microbial metabolic processes, although the exact molecular target remains an active area of investigation. Madhuri et al. (PMID: 18774890) reported KPV-related activity relevant to inflammatory and microbial research protocols. These findings have generated considerable interest in KPV as a tool for studying host-pathogen interaction at epithelial surfaces, where inflammation and microbial colonization frequently co-occur. For researchers designing protocols, it is worth noting that antimicrobial activity in buffered solution can differ substantially from activity in serum-containing media, so assay conditions should be standardized and documented.
What do preclinical IBD models reveal about KPV and gut inflammation?
Rodent models of inflammatory bowel disease (IBD) have been used extensively to characterize KPV activity in gut inflammation research. Published preclinical research indicates that KPV administered via oral, rectal, or systemic routes attenuates histopathological damage, weight loss, and colonic cytokine expression in dextran sulfate sodium (DSS) and trinitrobenzenesulfonic acid (TNBS) colitis models. Studies suggest that orally delivered KPV can transit a portion of the gastrointestinal tract intact and interact with intestinal epithelial cells, potentially via the PepT1 di/tripeptide transporter. This mode of uptake has made KPV a particularly interesting candidate for nanoparticle and targeted-delivery research protocols exploring mucosal anti-inflammatory strategies. Reductions in infiltrating neutrophils, myeloperoxidase activity, and key colonic cytokines have been documented across several laboratories. These findings position KPV as a valuable reference compound in IBD preclinical research, and researchers frequently include it as a positive control when benchmarking novel peptide-based anti-inflammatory candidates. For broader context on healing peptide research, see the healing peptides guide.
How does KPV compare with related peptides like BPC-157 and TB-500 in research?
KPV occupies a distinct mechanistic niche relative to other well-studied healing research peptides. BPC-157, a 15-amino-acid pentadecapeptide derived from gastric juice protein, is studied primarily in the context of tissue repair and gastrointestinal epithelial restitution, with proposed mechanisms involving growth factor signaling and angiogenesis. TB-500 (a fragment of Thymosin Beta-4) has been characterized in preclinical research for its roles in actin cytoskeletal dynamics and cell migration. KPV, by contrast, is primarily an anti-inflammatory tripeptide acting at the level of transcription factor regulation and cytokine release. Laboratories interested in combined mechanistic research protocols sometimes reference blended reference products such as the KLOW blend or the KLOW bundle, which are designed to support comparative in vitro and preclinical research. Published studies suggest that KPV’s small size and simple sequence make it a particularly well-behaved reagent for dose-response work, transporter studies, and mechanism dissection assays.
How should KPV be reconstituted and stored for research use?
Proper handling preserves peptide integrity and ensures reproducible experimental outcomes. KPV is shipped as a sterile lyophilized powder and should be stored at -20°C in its original sealed vial, protected from light and moisture, until reconstitution. For research use, KPV is typically reconstituted in bacteriostatic water for injection (containing 0.9% benzyl alcohol), sterile water for injection, or phosphate-buffered saline, depending on assay requirements. Diluent should be introduced slowly against the vial wall rather than directly onto the lyophilized pellet, and the vial should be swirled gently—not shaken vigorously—until the powder is fully dissolved. Once reconstituted, KPV solutions are generally maintained at 2-8°C and used within 28 days, with aliquoting into single-use fractions recommended to minimize freeze-thaw cycles. All work should be performed in a certified research environment by qualified personnel using appropriate personal protective equipment. These products are intended exclusively for laboratory use and not for human or animal consumption.
What analytical methods are used to confirm KPV purity and identity?
Quality-controlled research peptides are characterized using several orthogonal analytical techniques. Reversed-phase high-performance liquid chromatography (RP-HPLC) is the standard method for assessing KPV purity, typically targeting ≥98% by area integration at 214 nm. Mass spectrometry (commonly ESI-MS or MALDI-TOF) is used to confirm the expected monoisotopic mass of approximately 342.2 Da, providing definitive identity verification. Additional tests may include quantitative amino acid analysis, water content determination by Karl Fischer titration, and endotoxin testing for protocols that require low-endotoxin reagents. Certificates of analysis (CoA) accompanying research peptides typically summarize the results of these tests along with peptide content (mass of peptide per vial after accounting for counter-ions and water). Researchers designing quantitative experiments should always reference the CoA when preparing working solutions, because net peptide content can vary by 5-15% from the gross labeled mass depending on the specific lot and counter-ion salt form.
Frequently Asked Questions
1. What is KPV and how is it classified in peptide research?
KPV is a synthetic tripeptide consisting of the amino acids lysine, proline, and valine (Lys-Pro-Val), which corresponds to the C-terminal three residues of alpha-melanocyte-stimulating hormone (α-MSH). It is classified as an anti-inflammatory peptide fragment and is widely used in preclinical and cell-culture research to probe NF-κB-dependent signaling, cytokine regulation, and epithelial barrier biology. Unlike the parent α-MSH molecule, KPV does not contain the HFRW core motif required for pigmentation activity at MC1R, which makes it a selective research tool for investigating inflammation without confounding melanotropic effects. Published studies suggest KPV is active in multiple laboratory model systems at micromolar concentrations. All KPV sold on this site is classified strictly as a research chemical intended for laboratory use only and is not for human or animal consumption.
2. How does KPV differ from full-length α-MSH in research applications?
Full-length α-MSH is a 13-amino-acid peptide that engages all five melanocortin receptors (MC1R through MC5R) with varying affinity, exerting pleiotropic effects on pigmentation, energy balance, sebaceous gland activity, and inflammation. KPV, as the C-terminal tripeptide fragment, largely lacks classical melanocortin receptor agonism and instead exhibits a narrower research profile focused on anti-inflammatory activity. Preclinical research indicates that KPV reproduces many of α-MSH’s effects on NF-κB and cytokine expression without driving melanogenesis or significant appetite-related signaling. This selectivity is valuable in laboratory protocols aiming to isolate inflammation-related mechanisms from broader neuroendocrine effects. Researchers investigating melanocortin pharmacology often use α-MSH, KPV, and selective MC-receptor agonists in parallel to dissect pathway-specific contributions across the melanocortin system.
3. What cell and animal models are commonly used in KPV research protocols?
Published studies commonly employ intestinal epithelial lines such as Caco-2 and HT-29 for barrier function and cytokine research, macrophage lines (RAW 264.7, THP-1) for innate immune studies, and primary keratinocytes for skin-relevant inflammation work. Rodent models include DSS and TNBS colitis in mice and rats for IBD-relevant research, imiquimod-induced skin inflammation models, and various acute endotoxemia protocols. KPV is typically administered in vitro at concentrations ranging from 100 nM to 100 μM, and in rodent protocols at defined mg/kg ranges depending on route of administration (oral, intraperitoneal, or topical). Researchers should consult published methods sections and institutional biosafety protocols when designing studies. These laboratory applications are the sole context in which KPV from this supplier is intended to be used.
4. Does KPV cross the intestinal epithelium in preclinical models?
Preclinical research indicates that KPV can traverse the intestinal epithelium in laboratory model systems, at least in part via the PepT1 di/tripeptide transporter expressed on the apical surface of enterocytes. This transporter normally mediates absorption of dietary di- and tripeptides and displays broad substrate specificity. Published in vitro studies using Caco-2 monolayers and in vivo rodent absorption studies suggest that KPV can reach intracellular compartments of intestinal epithelial cells following oral delivery, where it can engage anti-inflammatory signaling. This property has generated interest in nanoparticle-based and prodrug research strategies for targeted epithelial delivery in IBD model protocols. Researchers studying transporter-mediated uptake may consider including PepT1 inhibitors or PepT1-knockout comparisons to confirm transporter dependence. These investigations are performed in laboratory research contexts only.
5. What solvents are compatible with KPV for laboratory reconstitution?
KPV is generally soluble in aqueous solvents including sterile water, bacteriostatic water (containing 0.9% benzyl alcohol), phosphate-buffered saline, and tissue culture media. For stock solution preparation, researchers typically reconstitute at 1-10 mg/mL and then dilute into experimental media. KPV does not require organic co-solvents such as DMSO for typical working concentrations, which is advantageous in cell-culture protocols where DMSO can itself modulate cellular behavior. Stock solutions should be prepared using filter-sterilized diluent under aseptic conditions and stored at 2-8°C for short-term use or -20°C in single-use aliquots for longer-term storage. Working solutions should be freshly diluted on the day of use when possible. All reconstitution activities should be performed by trained research personnel in appropriate laboratory facilities.
6. How should research-grade KPV be stored to maintain stability?
Lyophilized KPV is best stored at -20°C (or colder) in its original sealed vial, away from light and moisture. Under these conditions, stability of multiple years is typical for high-purity research peptides, although laboratories should rely on the specific stability data provided by their supplier’s certificate of analysis. Once reconstituted, KPV solutions are commonly stored at 2-8°C for up to 28 days or aliquoted and frozen at -20°C or -80°C for longer-term use. Repeated freeze-thaw cycles should be minimized, as they can degrade peptide integrity. Clearly label all vials with peptide name, concentration, diluent, date of reconstitution, and operator initials to support research reproducibility. These storage practices are for laboratory research handling only; KPV is not intended for human or animal consumption.
7. Where can researchers purchase high-purity KPV for laboratory use?
Peptideware supplies KPV as a sterile lyophilized research-grade peptide suitable for laboratory protocols. Each vial is accompanied by a certificate of analysis documenting identity (via mass spectrometry), purity (via HPLC), and peptide content. Our KPV 10mg research vial is designed for investigators studying α-MSH-derived anti-inflammatory signaling, NF-κB biology, candidacidal activity, and mucosal inflammation models. For protocols examining combined peptide mechanisms, the KLOW blend and KLOW bundle provide complementary research reagents. Orders are shipped in temperature-controlled packaging to preserve peptide integrity during transit. All products are sold strictly for laboratory and research purposes, not for human or animal consumption.
What directions are emerging in contemporary KPV research?
Contemporary KPV research continues to expand in several directions. Nanoparticle and hydrogel delivery systems are being explored as strategies to enhance mucosal targeting in preclinical IBD models, with early published work suggesting that encapsulation can increase local tissue concentrations while reducing systemic exposure. Structure-activity relationship studies have examined analogs of KPV containing D-amino acid substitutions, N-methylation, and PEGylation to probe the contributions of individual backbone features to anti-inflammatory activity. Mechanistic research is increasingly examining crosstalk between KPV-modulated NF-κB signaling and adjacent pathways including MAPK, JAK-STAT, and the NLRP3 inflammasome. Combination research protocols pair KPV with other immunomodulatory peptides or small molecules to characterize additive or synergistic effects in controlled laboratory settings. Across these directions, a unifying theme is the use of KPV as a well-behaved mechanistic probe whose small size, aqueous solubility, and selective anti-inflammatory activity make it a practical reagent for dissecting inflammation biology in a wide range of research systems.
Order KPV for Research
Access research-grade KPV for laboratory protocols investigating α-MSH-derived anti-inflammatory mechanisms, NF-κB signaling, and epithelial inflammation models.
Research Disclaimer: All products are intended for laboratory and research purposes only. Not for human or animal consumption. These statements have not been evaluated by the FDA. Products are not intended to diagnose, treat, cure, or prevent any disease. Use only in a certified research facility by qualified personnel following all applicable safety protocols and institutional guidelines.